Replies to post #427896 on Anavex Life Sciences Corp (AVXL)

[frrol]

Our "precision medicine" approach will likely prove helpful, given that S1 status (wild type vs mutant) is emerging as a primary efficacy factor. Our Partex deal is probably driven by this, where prospective patients would register and get genome screening. Our S1 agonists may prove therapeutic for certain AD, Rett, etc patients, hopefully most.